Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938232 | 0.82 | ERBB2 (0.53) | RECQLGRIN1GRIN2BEGFRERBB2 | |
| SCHEMBL2253448 | 0.82 | GRIN1 (0.45) | RECQLADRA2AGRIN1GRIN2BCYP1A2 | |
| SCHEMBL30803756 | 0.82 | GRIN1 (0.60) | GRIN1GRIN2BGABRA1GABRA5MEN1 | |
| SCHEMBL15687287 | 0.80 | ERBB2 (0.48) | RECQLGRIN1GRIN2BEGFRERBB2 | |
| SCHEMBL9941658 | 0.77 | GRIN1 (0.49) | GRIN1GRIN2BGABRA1GABRA5ALDH1A1 | |
| SCHEMBL29377752 | 0.77 | GLS (0.62) | GRIN1GRIN2BCYP1A2EGFRERBB2 | |
| SCHEMBL938567 | 0.77 | GLS (0.62) | GRIN1GRIN2BCYP1A2EGFRERBB2 | |
| SCHEMBL30918023 | 0.76 | RECQL (0.55) | RECQLADRA2ACYP1A2ERBB2KMO | |
| SCHEMBL30689171 | 0.75 | RECQL (0.58) | RECQLADRA2ACYP1A2KMO | |
| SCHEMBL248214 | 0.75 | RECQL (1.00) | RECQLADRA2ACYP1A2KMOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | RECQL 476/4885ADRA2A 3466/4885GRIN1 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.